Archives
Meta-analysis: Among the treatment interventions to maintain abstinence from alcohol in primary care, acamprosate was the only intervention with enough evidence of benefit
26 Nov, 2020 | 08:55h | UTC
Commentary on Twitter
Acamprosate was the only intervention with enough evidence of benefit for maintaining alcohol abstinence and acceptability up to 12 months after detoxification in primary care settings, concludes new #BMJResearchhttps://t.co/K7FutIC3yd
— The BMJ (@bmj_latest) November 25, 2020
Cohort study suggests there is no need to choose first-line drug treatment for hypertension according to age and ethnicity – guidelines could be simplified
26 Nov, 2020 | 08:56h | UTCCommentary: Study questions blood pressure drug guidance based on age and ethnicity – British Medical Journal AND Laurie Tomlinson: Shining a light into medicine’s dusty corners – The BMJ Opinion AND UK’s NICE Guidelines for Hypertension Tx Based on Age, Ethnicity May Need Updating – Physician’s Weekly AND
Commentary on Twitter
Current UK guidance on drug treatment for high blood pressure, which differs depending on a patient’s age and ethnicity, could be simplified in line with other international guidelines, suggests new @bmj_latest research @SarahJoSinnott https://t.co/bWLhXoFnV4
— The BMJ (@bmj_latest) November 21, 2020
Randomized trial: Nebulized magnesium does not benefit children with acute refractory asthma treated in the emergency department
26 Nov, 2020 | 08:58h | UTCEffect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial – JAMA (free for a limited period)
Commentary: Nebulized Magnesium Of Little Value for Emergency Tx of Kids’ Asthma Attacks – Physician’s Weekly
Commentary on Twitter
This RCT found that nebulized magnesium does not decrease hospitalization for children with refractory acute asthma in the emergency department, compared to albuterol or placebo https://t.co/9NjgPztY6V @sickkids #VisualAbstract
— JAMA (@JAMA_current) November 24, 2020
Randomized trial: Convalescent Plasma does not improve clinical status or overall mortality in severe Covid-19 pneumonia
25 Nov, 2020 | 09:17h | UTCCommentary: New trial of convalescent plasma for covid-19 falls flat, another setback for hyped treatment – Brief19
Commentary on Twitter
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia @NEJM A well conducted RCT shows no significant differences in clinical status or overall mortality between patients treated with CP and those who received placebo. https://t.co/C6NylbO2At
— Carlos del Rio (@CarlosdelRio7) November 24, 2020
Cluster-randomized trial: Postexposure hydroxychloroquine does not prevent Covid-19 in healthy persons exposed to a PCR-positive case patient
25 Nov, 2020 | 09:15h | UTC
Commentary on Twitter
Another RCT in @NEJM of outpatient treatment with Hydroxychloroquine in high risk folks to prevent COVID transmission
No benefit
But about 10X rate of adverse events in HCQ group
Happy to keep studying HCQ
But it really doesn't look like it workshttps://t.co/9nAfir0CMX
— Ashish K. Jha, MD, MPH (@ashishkjha) November 24, 2020
[Preprint] Study shows cloth face coverings help protect both wearers and those nearby. Study design represents conditions closer to real-world use, with the control of laboratory testing
25 Nov, 2020 | 09:11h | UTCStudy shows cloth face coverings help protect both wearers and those nearby – Virginia Tech
Original study: Inward and outward effectiveness of cloth masks, a surgical mask, and a face shield – medRxiv
Observational study: Neuraxial anesthesia for lower limb revascularization surgery was associated with decreased 30-day mortality and hospital length of stay compared with general anesthesia
26 Nov, 2020 | 08:53h | UTC
Commentary from the author on Twitter (thread – Click for more)
1/New in @bmj_latest our observational study demonstrating association of spinal anesthesia with ⬇️mortality & ⬇️complications in lower limb revascularization https://t.co/kqHLbRxju5
-OR mortality 0.68 (0.57-0.83)
ARR 0.7% (NNT 139)
-OR complications 0.73 (0.63-0.85) pic.twitter.com/jMEYaiMYPP— Dan McIsaac (@mcisaac_d) November 25, 2020
With more data on its COVID-19 vaccine, Russian institute offers new evidence of success
25 Nov, 2020 | 09:13h | UTCWith more data on its COVID-19 vaccine, Russian institute offers new evidence of success – Science
Commentaries: Expert reaction to press release reporting the second interim analysis of the efficacy of the Sputnik V vaccine – Science Media Centre AND Russia says Sputnik V virus vaccine 95% effective – MedicalXpress
Opinion: “Children may transmit coronavirus at the same rate as adults: what we now know about schools and COVID-19”
25 Nov, 2020 | 09:09h | UTC
Commentary from the author on Twitter
I've written a new article describing what we know about children, schools, & #COVID19.
➡️ Children & adults are equally susceptible, & likely transmit the virus at the same rate.
➡️ Schools are a driver of the second wave in Europe, Canada, & elsewhere.https://t.co/25T9HwHBlt
— Dr Zoë Hyde (@DrZoeHyde) November 24, 2020
Latest COVID-19 guidelines come out against bamlanivimab, remdesivir
25 Nov, 2020 | 09:10h | UTCLatest COVID-19 guidelines come out against bamlanivimab, remdesivir – ACP Internist
Systematic review: Financial payments from the pharmaceutical industry is associated with more physician prescribing of the drug made by the company that they got the payments from
25 Nov, 2020 | 09:07h | UTCAre Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? A Systematic Review – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary: Financial payments from drug industry associated with physician prescribing – American College of Physicians
Commentary from the author on Twitter (thread – click for more)
"Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing?"
Our latest on physician-industry COI is out today in @AnnalsofIM!Not to bury the lede, the answer is "yes."
Thread to follow.https://t.co/2lfAjWSQuq
1/— Aaron Mitchell (@TheWonkologist) November 24, 2020
Randomized trial: Prednisone is an effective short-term preventive therapy in patients with episodic cluster headache
25 Nov, 2020 | 09:01h | UTCSafety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial – The Lancet Neurology (link to abstract – $ for full-text)
Commentary from the author on Twitter
Finally published online! After countless years and a lot of work our study on prednisone for the treatment of episodic cluster headache. Thanks to all the many people that were involved in this study, Very proud!!! #PredCH #Clusterheadachehttps://t.co/d88TUWTY5i
— Mark Obermann (@ProfObermann) November 25, 2020
Randomized trial: Colorectal cancer screening with repeated fecal immunochemical tests detects more colorectal cancer and advanced adenomas compared to screening sigmoidoscopy
25 Nov, 2020 | 09:05h | UTCColorectal cancer screening with repeated fecal immunochemical test versus sigmoidoscopy: baseline results from a randomized trial – Gastroenterology (link to abstract – $ for full-text)
USPSTF Statement recommends regular behavioral counseling on healthy diet and physical activity to prevent cardiovascular disease
25 Nov, 2020 | 08:59h | UTCAuthor interview: Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors
JAMA Patient Page: Counseling on Healthy Diet and Physical Activity to Prevent Cardiovascular Disease
Kids’ COVID cases on the rise, but most are mild, new studies show
24 Nov, 2020 | 09:35h | UTCKids’ COVID cases on the rise, but most are mild, new data show – CIDRAP
Diagnosis, management, and pathophysiology of arterial and venous thrombosis in COVID-19
24 Nov, 2020 | 09:34h | UTCDiagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19 – JAMA
Commentary on Twitter
Arterial and venous thrombosis are common in #COVID19, especially in critically ill patients. Thromboprophylaxis should be considered for all hospitalized patients with COVID-19 in the absence of contraindications https://t.co/sjqL7MqGLX
— JAMA (@JAMA_current) November 23, 2020
Why does the AstraZeneca-Oxford COVID-19 vaccine’s efficacy vary so much? Here’s what we know
24 Nov, 2020 | 09:30h | UTCWhy Does the AstraZeneca COVID-19 Vaccine’s Efficacy Vary So Much? Here’s What We Know – TIME
Related: Why Oxford’s positive COVID vaccine results are puzzling scientists – Nature
Why the AstraZeneca-Oxford Covid-19 vaccine is different. It does not require extremely cold temperatures for storage, and the price will be “a fraction” of the expense of the other vaccine candidates
24 Nov, 2020 | 09:32h | UTCWhy the AstraZeneca-Oxford Covid-19 vaccine is different – Vox
Four reasons why we need multiple vaccines for Covid-19
24 Nov, 2020 | 09:27h | UTCFour reasons why we need multiple vaccines for Covid-19 – Wellcome Trust
Emergency COVID-vaccine approvals pose a dilemma for scientists. It could complicate efforts to study long-term outcomes, such as safety, how long protection lasts and whether the jab prevents infection or just the disease
24 Nov, 2020 | 09:28h | UTCWhy emergency COVID-vaccine approvals pose a dilemma for scientists – Nature
Data show hospitalized Covid-19 patients are surviving at higher rates, but surge in cases could roll back gains
24 Nov, 2020 | 09:25h | UTC
Opinion – Football and dementia: heading must be banned until the age of 18
24 Nov, 2020 | 09:24h | UTCFootball and dementia: heading must be banned until the age of 18 – The Conversation
Podcast: Diabetes Triple Distilled. Pitfalls of A1c testing, different guidelines for A1C targets, when and how to use the newer medications such as SGLT-2 inhibitors and GLP-1 agonists, and more
24 Nov, 2020 | 09:03h | UTC#243 Diabetes Triple Distilled – The Curbsiders Internal Medicine Podcast
Covid-19: Oxford University vaccine shows 70% protection
23 Nov, 2020 | 09:54h | UTCCovid-19: Oxford University vaccine shows 70% protection – BBC
News release: Oxford University breakthrough on global COVID-19 vaccine
Commentary on Twitter
Today marks an important milestone in the fight against #COVID19. Interim data show the #OxfordVaccine is 70.4% effective, & tests on two dose regimens show that it could be 90%, moving us one step closer to supplying it at low cost around the world>> https://t.co/fnHnKSqftT pic.twitter.com/2KYXPxFNz1
— University of Oxford (@UniofOxford) November 23, 2020
Randomized, placebo-controlled, crossover trial: Amantadine, modafinil, and methylphenidate are no better than placebo for fatigue in multiple sclerosis
24 Nov, 2020 | 09:02h | UTCSafety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial – The Lancet Neurology (link to abstract – $ for full-text)